🇺🇸 FDA
Pipeline program

Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

M15-954

Phase 3 small_molecule active

Quick answer

Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use for Higher-Risk Myelodysplastic Syndrome is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Higher-Risk Myelodysplastic Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials